National Heart, Lung, and Blood Institute; Notice of Closed Meetings, 71080 [2020-24670]
Download as PDF
<![CDATA[
71080
Federal Register / Vol. 85, No. 216 / Friday, November 6, 2020 / Notices
NIH ref No.
Patent No. or
application No.
Issue date
Filing date
E–140–2014–0–EP–06 ..........
E–140–2014–0–IN–07 ...........
E–140–2014–0–JP–08 ...........
E–140–2014–0–US–09 ..........
E–140–2014–0–HK–10 ..........
E–140–2014–0–AU–11 ..........
15728668.3 ...................
201637038171 ..............
2017–511558 ................
10,329,259 ....................
17105705.6 ...................
2019227889 ..................
...............................................
...............................................
TBD (application allowed) ....
June 25, 2019 ......................
...............................................
...............................................
May 8, 2015 .................
November 8, 2016 ........
May 8, 2015 .................
November 8, 2016 ........
June 9, 2017 ................
May 8, 2015 .................
The patent rights in these inventions
have been assigned to the Government
of the United States of America.
The prospective exclusive patent
license territory may be worldwide and
a field of use limited to human
therapeutics for Hermansky-Pudlak
syndrome and idiopathic pulmonary
fibrosis.The invention covered by the
patents and patent applications
pertaining to HHS Ref. No. E–282–2012
relates to cannabinoid receptor 1 (CB1R)
inverse agonists. CB1R activation plays
a key role in appetitive behavior,
metabolism, and tissue fibrosis. Of
importance as a therapeutic target here
is that the receptor is expressed in both
peripheral tissue as well as the central
nervous system. The invention is a class
of pyrazole compounds that act as CB1
receptor inverse agonists and have been
shown effective at reducing obesity and
its associated metabolic consequences
while having no experimentally
discernable neuropsychotropic side
effects that are considered adverse,
unlike the earlier antagonists
rimonabant. These CB1R receptor
compounds were developed with the
goals of limiting their brain penetrance
without losing their metabolic efficacy
due to CB1 inverse agonism, and having
a primary metabolite directly targeting
enzymes involved in inflammatory and
fibrotic processes associated with
metabolic and other disorders. The
patents are both compositions of matter
and methods of use.
The inventions covered by HHS Ref.
E–140–2014–0 also pertain to pyrazole
CB1R receptor inverse agonists. In
addition, some of these compounds also
have a direct inhibitory effect on
inducible nitric oxide synthase (iNOS),
whereas another group of the
compounds directly activates AMP
kinase. There is evidence that the
metabolic effects of endocannabinoids
are mediated by CB1 receptors in
peripheral tissues. These dual-target
compounds may be useful for treating
metabolic disease and related
conditions such as obesity and diabetes
and their complications, including
various forms of tissue fibrosis, without
the dangerous side effects. This notice is
made in accordance with 35 U.S.C. 209
and 37 CFR part 404. The prospective
exclusive patent license will be royalty
VerDate Sep<11>2014
19:00 Nov 05, 2020
Jkt 253001
bearing and may be granted unless
within fifteen (15) days from the date of
this published notice, NHGRI receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in
the prospective field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive patent
license.
Comments and objections submitted
to this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: November 2, 2020
Claire T. Driscoll,
Director, Technology Transfer Office,
National Human Genome Research Institute.
[FR Doc. 2020–24616 Filed 11–5–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
R13 Conferences and Scientific Meetings.
Date: December 11–14, 2020.
Time: 11:00 a.m. to 7:30 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
Title
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Cannabinoid
Receptor
Receptor
Receptor
Receptor
Receptor
Receptor
Mediating
Mediating
Mediating
Mediating
Mediating
Mediating
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Compounds.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20814 (Virtual Meeting).
Contact Person: Keith A Mintzer, Ph.D.,
Scientific Review Officer, Office of Review
Branch/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 207–G,
Bethesda, MD 20892–7924, (301) 827–7949,
mintzerk@nhlbi.nih.gov.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
NHLBI Institutional Training Grants.
Date: December 15, 2020.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge I, 6705 Rockledge Drive, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Giuseppe Pintucci, Ph.D.,
Scientific Review Officer, Office of Scientific
Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health,
6705 Rockledge Drive, Room 205–H,
Bethesda, MD 20892, (301) 827–7969,
Pintuccig@nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: November 2, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–24670 Filed 11–5–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
E:\FR\FM\06NON1.SGM
06NON1
]]>Agencies
[Federal Register Volume 85, Number 216 (Friday, November 6, 2020)]
[Notices]
[Page 71080]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-24670]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; R13 Conferences and Scientific Meetings.
Date: December 11-14, 2020.
Time: 11:00 a.m. to 7:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge I, 6705
Rockledge Drive, Bethesda, MD 20814 (Virtual Meeting).
Contact Person: Keith A Mintzer, Ph.D., Scientific Review
Officer, Office of Review Branch/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6705 Rockledge
Drive, Room 207-G, Bethesda, MD 20892-7924, (301) 827-7949,
[email protected].
Name of Committee: National Heart, Lung, and Blood Institute
Special Emphasis Panel; NHLBI Institutional Training Grants.
Date: December 15, 2020.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge I, 6705
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Giuseppe Pintucci, Ph.D., Scientific Review
Officer, Office of Scientific Review/DERA, National Heart, Lung, and
Blood Institute, National Institutes of Health, 6705 Rockledge
Drive, Room 205-H, Bethesda, MD 20892, (301) 827-7969,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: November 2, 2020.
Ronald J. Livingston, Jr.,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-24670 Filed 11-5-20; 8:45 am]
BILLING CODE 4140-01-P
